Loxapine (succinate)

Loxapine (succinate)

• CAS Number: 27833-64-3
• UNSPSC Description: Loxapine succinate is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent. Loxapine can also suppresses bacterial efflux pump activity and inhibit intracellular multiple-antibiotic-resistant Salmonella enterica serovar Typhimurium in macrophages[1][4][6].
• Target Antigen: 5-HT Receptor; Dopamine Receptor
• Type: Reference compound
• Related Pathways: GPCR/G Protein;Neuronal Signaling
• Applications: Neuroscience-Neuromodulation
• Field of Research: Infection; Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/Loxapine-succinate.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : 2.5 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: O=C(O)CCC(O)=O.CN1CCN(C2=NC3=CC=CC=C3OC4=CC=C(Cl)C=C24)CC1
• Molecular Weight: 445.90
• References & Citations: [1]Singh AN, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci. 1996 Jan;21(1):29-35.|[2]Labuzek K, et al. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol. 2005 Jan;15(1):23-30.|[3]Lee T, et al. Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res. 1984 Aug;12(4):277-85.|[4]Keating GM. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS Drugs. 2013 Jun;27(6):479-89.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched